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Improved classification of leukemic B-cell 
lymphoproliferative disorders using a transcriptional
and genetic classifier 
B-cell chronic lymphoproliferative disorders (B-CLPD)
encompass a group of hematologic tumors that often
present with leukemic involvement.1 Their heterogeneity
and the lack of relatively specific diagnostic markers for
most of these diseases make their diagnosis challenging,
especially in cases that only have blood involvement or
when histology is not available. With the currently used
immunophenotypic and molecular markers, around 10%
of B-CLPD cases remain unclassifiable and are catego-
rized as B-CLPD, not otherwise specified (B-CLPD,
NOS). Few recurrent gene mutations and chromosomal
abnormalities have been documented in some entities:
BRAF and MYD88mutations in hairy cell leukemia (HCL)
and lymphoplasmacytic lymphoma (LPL), respectively,2,3
in addition to the recurrent 7q31-q32 deletion in splenic
marginal zone lymphoma (SMZL).1 However, none of
them are diagnostic hallmarks of any particular entity.
Gene expression profiling studies have recognized specif-
ic signatures that identify most common hematological
neoplasms.4,5 Based on these results we postulated that
the analysis of the gene expression profiling (GEP) of a
large series of leukemic B-CLPD could identify specific
signatures for each leukemic disease entity. These signa-
tures could be useful for the classification of cases with
undetermined diagnosis  (B-CLPD, NOS). In this study,
we have investigated the GEP of a large series of
leukemic lymphoid neoplasms and identified specific
gene signatures for most entities that were validated in
an independent cohort. We have also derived and validat-
ed a simplified quantitative polymerase chain reaction
(qPCR)-based 8-gene assay that reliably recognized these
entities and could assist in the diagnosis in routine prac-
tice, particularly in atypical cases and B-CLPD, NOS. 
We initially studied the global GEP (Affymetrix
U133+2.0 arrays, GEO GSE79196) of 159 well-defined
leukemic B-cell neoplasms with highly purified tumor
cells (mean 96%, range 79-100%; training series) (Online
Supplementary Figure S1). The diagnosis was established
in the peripheral blood (PB) based on cytology,
immunophenotype, and, in some cases, cytogenetics
according to the World Health Organization (WHO) clas-
sification.1 These cases included 54 chronic lymphocytic
leukemia (CLL), 30 conventional and 24 leukemic non-
nodal mantle cell lymphoma (cMCL and nnMCL, respec-
tively), 12 follicular lymphoma (FL), 4 HCL, 4 HCL vari-
ant (HCLv), 4 LPL, 23 SMZL, and 4 splenic diffuse red
pulp lymphomas (SDRPL). Subsequent biopsies obtained
in 70 cases, including all SMZL and SDRPL were
reviewed (Online Supplementary Table S1). We investigat-
ed 30 additional cases considered leukemic B-CLPD,
NOS because they did not have the diagnostic features
characteristic of a specific disease entity, lacked spleen
histology in splenomegalic disorders, and/or had unusual
features for a given entity such as CLL with BCL2
rearrangements. All these B-CLPD, NOS also had high
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Figure 1. Molecular diagnostic signatures of 159 leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) and 30 B-CLPD, not otherwise specified
(NOS). Heatmap representing the genes identified at each step of the GEP55. Each column represents a B-CLPD patient and each row represents a gene. Most
genes showed differential high expression (blue), whereas only 1, 2 and 5 genes showed low expression for chronic lymphocytic leukemia (CLL), follicular lym-
phoma (FL), and hairy cell leukemia variant (HCLv), respectively. In the right part of each entity the B-CLPD, NOS (white) are classified according to their expres-
sion. For each gene only relevant samples of the multistep approach are shown. cMCL: conventional mantle cell lymphoma; HCL; hairy cell leukemia; nnMCL:
non-nodal mantle cell lymphoma; LPL: lymphoplasmacytic lymphoma; SDRPL; splenic diffuse red pulp lymphoma; SMZL: splenic marginal zone lymphoma.  
tumor cell content (mean 96%, range 94-100%). The
study was approved by the Institutional Review Board of
the Hospital Clinic of Barcelona. 
The GEP of this series was first analyzed by an unsu-
pervised hierarchical clustering approach. The cases were
distributed into 2 main branches: 1 exclusively comprised
CLL, whereas the other included MCL, FL, HCL, and
HCLv, which were grouped together according to their
respective diagnosis. The 30 B-CLPD, NOS cases were
distributed among the different well-defined entities,
suggesting that they may correspond to these respective
diseases (Online Supplementary Figure S2). To identify the
specific gene expression signatures of the different enti-
ties, we developed a 6-step GEP predictor model using 55
genes (GEP55; Figures 1 and 2A, Online Supplementary
Methods, and Online Supplementary Table S2). Nine genes
were specific for CLL and separated the 54 CLL from the
other disorders. Subsequently, 30 cMCL were identified
using 16 genes, then HCL was separated using 5 genes
(Online Supplementary Figure S3), and the following step
classified 12 FL based on the expression of 14 genes.
Once cMCL and HCL were classified, CCND1 expression
identified the 24 nnMCL. Finally, the lack of CXCR4
expression, together with the deregulation of another 9
genes, specifically identified the 4 HCLv. We were unable
to determine distinct signatures for the 31 LPL, SMZL,
and SDRPL, thus these 3 diseases were considered as a
miscellaneous group. This latter finding correlates with
the overlapping cytology and immunophenotype of these
diseases.6 In summary, the GEP55 model discriminated
most entities with high sensitivity (77-100%) and speci-
ficity (89-100%), except for the miscellaneous group
(Online Supplementary Table S2). 
We next applied the GEP55 model to the subset of 30
B-CLPD, NOS. Ten (33%) were classified by GEP as 7
CLL, 1 cMCL, and 2 HCL (Figure 3A,B and Online
Supplementary Table S3). To determine whether addition-
al genetic and molecular studies could improve the clas-
sification of the B-CLPD, NOS cases we performed the
mutational analysis of BRAF, MAP2K1, MYD88,
NOTCH1, NOTCH2, SF3B1, and TP53 by Sanger
sequencing7 and investigated chromosomal alterations by
cytogenetics and/or Affymetrix SNP 6.0 microarrays.8
Combining the GEP with this molecular information,
10/20 of the remaining B-CLPD, NOS were classified: 6
SMZL based on the presence of NOTCH2 mutations, 2
SMZL based on concurrent trisomy 3 and 12 and absence
of paraprotein, and 2 LPL based on MYD88 mutations
(Online Supplementary Figure S4). Although 10/30 (33%)
B-CLPD, NOS remained unclassifiable, we could rule out
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Figure 2. Schematic representation of the predictor models. (A) Box flow chart of the gene expression profiling GEP55. The successive steps and the number
of cases per entity used to build the model are shown in boxes. In the lower part, the genes used for the classification in each step are indicated. In bold, the
genes that were later selected for quantitative polymerase chain reaction (qPCR) analysis. This GEP55 was also used to classify 30 B-cell chronic lymphopro-
liferative disorders, not otherwise specified (B-CLPD, NOS) cases. (B) Box flow chart of the qPCR model. In the upper part, the successive steps and the number
of cases from the qPCR training and independent validation series. In the lower part, the number of cases of each entity used to build the qPCR model and the
genes used at each step. This qPCR model was also used to classify 34 B-CLPD cases. CLL: chronic lymphocytic leukemia; cMCL: conventional mantle cell lym-
phoma; HCL; hairy cell leukemia; FL: follicular lymphoma; nnMCL: non-nodal mantle cell lymphoma; HCLv; hairy cell leukemia variant. LPL: lymphoplasmacytic
lymphoma; SDRPL; splenic diffuse red pulp lymphoma; SMZL: splenic marginal zone lymphoma.
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the diagnosis of the well-defined entities (CLL, FL, cMCL,
nnMCL, HCL, and HCLv; Figure 3B). Overall, the combi-
nation of GEP55 and additional genetic data helped to
accurately classify 20/30 (67%) B-CLPD, NOS. 
To develop a simple qPCR assay that could be used in
routine diagnosis we reanalyzed the GEP of the 159
cases. We selected a subset of genes representative of
each disease and measured their expression by qPCR
(Fluidigm BioMark 48.48 Dynamic Array, Fluidigm®) in
44 samples previously examined by microarrays (Figure
2B, Online Supplementary Methods, Online Supplementary
Table S4, and Online Supplementary Figures S1 and S5).
Subsequently, we selected 8 genes that corresponded to
the minimal number that reliably recognized the different
entities, except the miscellaneous group. The final qPCR
8-gene step-wise predictor included FMOD and KSR2 for
CLL, SOX11 for cMCL, MYOF for HCL, MME for FL,
CCND1 for nnMCL, and CXCR4 and CAMSAP2 for
HCLv (Online Supplementary Table S5 and Online
Supplementary Figure S6). Next, we applied this 8-gene
predictor model to an independent validation series of 63
leukemic B-CLPD (mean tumor cell content 81%, range
60-99.9%). We confirmed the classification of CLL,
cMCL, FL, and nnMCL in all cases (confidence interval =
(94.3%-100%); Figure 2B and Online Supplementary Figure
S1). As expected, LPL and SMZL remained in the miscel-
laneous group. We did not observe differences in the clas-
sification based on the tumor cell content (60-80% vs. 81-
99.7%). Moreover, we performed serial dilution experi-
ments (100%-70%-40%-20%) in 8 samples (2 CLL, 2
cMCL, 1 HCL, 1 FL, 1 nnMCL, and 1 HCLv). All entities
were correctly identified with 70% tumor cells, and CLL,
cMCL, and nnMCL were correctly classified even with
40% tumor cells. The 8-gene predictor model was then
applied to 34 additional B-CLPD, NOS (mean 81% tumor
cells, range 60-99.9%) and it classified 19/34 (56%) as 14
CLL, 1 FL, 3 HCLv, and 1 nnMCL. Additional
molecular/genetic features helped to classify 4 additional
cases in the miscellaneous group as LPL based on MYD88
mutations (Figure 3C and Online Supplementary Table S6).
Finally, 11/34 (32%) cases remained unclassified. In sum-
mary, this simple 8-gene qPCR-model together with
molecular analysis accurately classified 100% of the 
well-defined entities in addition to 68% B-CLPD, NOS.
Taken together, these results show that the GEP55 and
the simplified 8-gene qPCR models contribute to the pre-
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Figure 3. Classification flow charts of the B-cell chronic lymphoproliferative disorders, not otherwise specified (B-CLPD, NOS) patients from the gene expres-
sion profiling (GEP) and quantitative polymerase chain reaction (qPCR) series. (A) Flow diagram of the steps of B-CLPD classification, based on gene expression
and other molecular/genetic data such as 7q deletion and/or NOTCH2 mutation (for SMZL) and MYD88 mutation for LPL classification. (B) Classification of 30
B-CLPD, NOS cases of the GEP series: i) 10 cases were classified by GEP only; 7 as CLL (including 3 with BCL2 rearrangements) and 1 as cMCL (lacking
t(11;14)(q13;q32) but positive for the IGL/CCND2 rearrangement) and 2 cases in which a definitive diagnosis could not be established in the initial sample
(due to the low number of circulating neoplastic cells) were classified as HCL by GEP alone, ii) 10 cases by combining GEP with molecular/genetic features; 2
as LPL (MYD88 mutations), and 8 as SMZL (NOTCH2 mutations and 7q deletion in 6 cases and 3q and chromosome 12 gains in the remaining 2 cases), and
iii) 10 cases remained in the miscellaneous group of LPL, SMZL, and SDRPL. (C) Classification of 34 B-CLPD, NOS cases using the 8-gene qPCR model: i) 19
cases were classified by qPCR only; 14 as CLL (9 with t(14;19)(q32;q13) involving IGH and BCL3 loci), 1 as FL (with add(14)(q32) but without t(14;18)(q32;q21)
by fluorescence in situ hybridization, 3 HCLv, and 1 nnMCL, ii) 4 cases classified as LPL by combining qPCR with molecular features (MYD88 mutations), and
iii) 11 cases remained in the miscellaneous group of LPL, SMZL, and SDRPL. RNA; ribonucleic acid; CLL: chronic lymphocytic leukemia; cMCL: conventional
mantle cell lymphoma; HCL; hairy cell leukemia; FL: follicular lymphoma; nnMCL: non-nodal mantle cell lymphoma; HCLv; hairy cell leukemia variant; LPL: lym-
phoplasmacytic lymphoma; SDRPL; splenic diffuse red pulp lymphoma; SMZL: splenic marginal zone lymphoma. 
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cise diagnosis of B-CLPD, particularly in cases with atyp-
ical/inconclusive phenotypes or unusual features (B-
CLPD, NOS) with the exception of the miscellaneous
group. Interestingly, atypical cases such as CLL with
atypical phenotypes or carrying the t(14;18)(q32;q21) or
t(14;19)(q32;q13), cyclin D1-negative cMCL and
leukemic FL without the t(14;18)(q32;q21) were clearly
assigned to their specific categories. Moreover, both
expression assays could assign 45% of the B-CLPD, NOS
to a specific disease based solely on gene expression data.
The addition of a small subset of genetic/molecular stud-
ies (i.e., NOTCH2 mutation and 7q deletion in SMZL,
and MYD88 mutation in LPL) refined the diagnosis of the
miscellaneous group, increasing the total number of clas-
sified cases by up to 67%. However, as MYD88 muta-
tions with or without an immunoglobulin M (IgM) band
are also detected in CLL9 and NOTCH2 mutations in FL10
and MCL,8 a definitive diagnosis without the information
of gene expression would have been difficult. Thus, the
contribution of GEP or qPCR assays allowed us to
exclude all these diseases, and instead allocate these
cases into the miscellaneous group (LPL, SMZL, SDRPL). 
Overall, our GEP analysis expanded upon previous
reports, highlighting that most leukemic B-CLPD have
specific expression profiles, even if they present with
atypical features. The most distinct was CLL (high
FMOD, LEF1, and KSR2),11 followed by cMCL (high
SOX11, DBN1, and HDGFRP), nnMCL (high
CCND1),12,13 FL (high MME), and HCL (high IL1R2,
ANXA1, and MYOF).14 Of interest was our finding of a
distinct gene signature for HCLv (low CXCR4 and high
CAMSAP2), a disease that still is a provisional entity in
the WHO classification,1,15 however, further studies are
needed to confirm this finding due to the small number
of HCLv analyzed. 
In summary, we describe a "ready to use" 8-gene qPCR
prediction assay which can be helpful in the classification
of leukemic B-CLPD in routine practice, particularly in
cases with atypical or non-specific features. The combi-
nation of this assay with additional molecular and genet-
ic studies may improve the diagnosis of these entities.
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